×
About 5,278 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  1,243 results

Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Wi...
https://doi.org/10.1161/JAHA.121.025192
Journal of the American Heart Association; Bellows BK, Khera AV et. al.

May 19th, 2022 - Background Heterozygous familial hypercholesterolemia (FH) is a common genetic disorder causing premature cardiovascular disease. Despite this, there is no national screening program in the United States to identify individuals with FH or likely p...

Screening of ABCG5 and ABCG8 Genes for Sitosterolemia in a Familial Hypercholesterolemi...
https://doi.org/10.1161/CIRCGEN.121.003390
Circulation. Genomic and Precision Medicine; Tada MT, Rocha VZ et. al.

May 14th, 2022 - Sitosterolemia is a rare autosomal recessive disorder caused by homozygous or compound heterozygous variants in ABCG5/ABCG8. The disease is characterized by increased plasma plant sterols. Small case series suggest that patients with sitosterolemi...

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
https://clinicaltrials.gov/ct2/show/NCT02808403

May 11th, 2022 - The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history)...

Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Em...
https://doi.org/10.2174/1871530322666220509040844
Endocrine, Metabolic & Immune Disorders Drug Targets; Taheri F, Taghizadeh E et. al.

May 10th, 2022 - Familial hypercholesterolemia (FH) as a high-frequency genetic disorder is diagnosed based on family and/or patient's history of coronary heart disease (CHD) or some other atherosclerotic disease, LDL-C levels and/or clinical signs such as tendono...

Effect of Breastfeeding on Lipid Profile and Cardiovascular Risk Markers in Women With Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT05367310

May 10th, 2022 - Patients with familial hypercholesterolemia (FH) have elevated plasma levels of LDL-cholesterol from first years of life. Cholesterol burden through life defines risk of cardiovascular disease. In women with FH, cholesterol levels increase during ...

see more →

Guidelines  3 results

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 12th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task ...
https://doi.org/10.1001/jama.2016.9852
JAMA , Bibbins-Domingo K et. al.

Aug 18th, 2016 - Elevations in levels of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser extent, elevated triglyceride levels are associated with risk of cardiovas...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 18th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

see more →

Drugs  406 results see all →

Clinicaltrials.gov  62 results

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
https://clinicaltrials.gov/ct2/show/NCT02808403

May 11th, 2022 - The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history)...

Effect of Breastfeeding on Lipid Profile and Cardiovascular Risk Markers in Women With Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT05367310

May 10th, 2022 - Patients with familial hypercholesterolemia (FH) have elevated plasma levels of LDL-cholesterol from first years of life. Cholesterol burden through life defines risk of cardiovascular disease. In women with FH, cholesterol levels increase during ...

Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT04837638

Apr 29th, 2022 - The proposed research will deploy as cross-sectional study including treated adults with genetically-defined HeFH. Once recruited, participants will be asked to complete web-based questionnaires on diet, medication and lifestyle. They will thereaf...

Study of Awareness and Detection of Familial Hypercholesterolemia
https://clinicaltrials.gov/ct2/show/NCT01960244

Apr 26th, 2022 - The FH Foundation CASCADE-FH Registry will implement an enrollment framework which is characterized by three possible points of contact: 1) Clinic enrollment 2) Self-enrollment through an online patient portal, and 3) Electronic Health Record (EHR...

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).
https://clinicaltrials.gov/ct2/show/NCT05325203

Apr 13th, 2022 - A randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of JS002 in patients with heterozygous familial hypercholesterolemia. 120 subjects are planned to be enrolled. Each subject is required a ma...

see more →

News  392 results

Early Treatment May Delay Atherosclerosis in Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/969991

Mar 9th, 2022 - Patients with familial hypercholesterolemia (FH) who start lipid-lowering treatment earlier in life may reduce their cardiovascular risk, compared with those who don't begin treatment early, according to results of a recent meta-analysis. They sho...

Early treatment may delay atherosclerosis in familial hypercholesterolemia
https://www.mdedge.com/cardiology/article/252467/cad-atherosclerosis/early-treatment-may-delay-atherosclerosis-familial
Jeff Craven

Mar 7th, 2022 - Patients with familial hypercholesterolemia (FH) who start lipid-lowering treatment earlier in life may reduce their cardiovascular risk, compared with those who don’t begin treatment early, according to results of a recent meta-analysis. They sho.

FDA Approvals, Highlights, and Summaries: Family Medicine
https://www.medscape.com/viewarticle/967605

Feb 17th, 2022 - Cardiology Leqvio (inclisiran) Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisi...

FDA Approvals, Highlights, and Summaries: Health Care Practitioners
https://www.medscape.com/viewarticle/968080

Feb 17th, 2022 - Cardiology Leqvio (inclisiran) Inclisiran is a double-stranded small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes. In hepatocytes, inclisi...

Recent Clinical Advances in Reducing Risk for Dyslipidemia
https://www.medscape.com/viewarticle/958749

Feb 15th, 2022 - This transcript has been edited for clarity. Laurence Sperling, MD: Welcome to Medscape InDiscussion. We have two national and world experts with us here today, and I'm excited about our discussion. This morning, we'll start off with a case and th...

see more →

Patient Education  5 results see all →